Related Experiment Video
Updated: Dec 25, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
PD1/PD-L1 Axis in Uro-oncology
Kerstin Junker1, Markus Eckstein2, Michelangelo Fiorentino3
1Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany
Abstract:
The immune system is important to control tumor development and progression in humans. However, tumor cells and cells of the tumor microenvironment can induce immune escape mechanisms including activation of immune checkpoints such as PD-1/PD-L1. Based on this knowledge, new immune therapies, including PD-1 and PD-L1 inhibition, have been developed and are already recommended as a standard treatment in metastatic bladder and kidney cancer patients. In addition to its role as a therapeutic target, PD-L1 seems to be a prognostic parameter although data are controversial. Only little is known about signaling pathways inducing PD-L1 expression in tumor cells on one hand and about its functional role for tumor cells itself. However, the understanding of the complex biological function of PD-L1 will improve therapeutic options in urological malignancies. This review is giving an overview of the current knowledge concerning the PD-1/PD-L1 axis in urological tumors including bladder, kidney, prostate, testicular and penile cancer.
Insights
The programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) axis is crucial in cancer immunity and a target for new therapies. Understanding PD-L1 in urological tumors can improve treatment options.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- The immune system regulates tumor development, but cancer cells can evade immune detection via mechanisms like PD-1/PD-L1 immune checkpoint activation.
- PD-1/PD-L1 inhibitors are established treatments for metastatic bladder and kidney cancers.
- PD-L1's prognostic value is debated, and its signaling pathways and functional roles in tumor cells require further investigation.
Purpose of the Study:
- To review the current understanding of the PD-1/PD-L1 axis in various urological malignancies.
- To explore the role of PD-L1 in tumor immune escape and its potential as a prognostic marker.
- To highlight the implications of PD-L1 function for future therapeutic strategies in urological cancers.
Main Methods:
- Literature review of studies on the PD-1/PD-L1 axis in urological tumors.
- Analysis of data regarding PD-L1 expression, its prognostic significance, and therapeutic targeting.
- Synthesis of information on signaling pathways and functional roles of PD-L1 in cancer cells.
Main Results:
- The PD-1/PD-L1 pathway is a key mechanism for tumor immune evasion in urological cancers.
- PD-1/PD-L1 inhibitors have demonstrated efficacy in treating advanced bladder and kidney cancers.
- Controversial data exist regarding PD-L1's prognostic role, necessitating further research into its complex functions.
Conclusions:
- The PD-1/PD-L1 axis is a significant factor in the immune response to urological tumors.
- Further research into PD-L1 signaling and function is essential for optimizing immunotherapies in urological malignancies.
- A comprehensive understanding of PD-L1 biology will enhance therapeutic outcomes for patients with bladder, kidney, prostate, testicular, and penile cancers.
